Fig. 2: sTILs were evaluated via manual assessment and with MuTILs. | npj Breast Cancer

Fig. 2: sTILs were evaluated via manual assessment and with MuTILs.

From: Spatial biomarkers of response to eribulin plus pembrolizumab in patients with metastatic triple negative breast cancer in the ENHANCE-1 trial

Fig. 2

Pathologist-assessed sTILs stratified by response across all samples and the TME-naive subset in (A) primary and metastatic sites and (B) the primary site. MuTILs computationally assessed sTILs in breast samples compared to pathologist assessed sTILs and stratified by response (C) and the TME-naive subset in breast samples (D).

Back to article page